Skip to main content

Table 2 Influence of device-associated health care-associated infections on length of stay and additional cost of therapy. Data is showed as numerical values, median values (IQR), 95% CI

From: Device associated –health care associated infections monitoring, prevention and cost assessment at intensive care unit of University Hospital in Poland (2015–2017)

 

Average LOS of patient with HAIs,

n (IQR),95%CI

Average LOS of patient with no HAIs

n (IQR),95%CI

Extra LOS of patient with HAIs, n

Extra cost of therapy caused by HAIs

One infection

21(14–33),95%CI(27.72–28.7)

6.0 (3–11),95%CI(8.27–9.42)

15

US$ 11,475

€ 10,035

Multiple infections

39.5(31–51),95%CI(35.68–49.41)

6.0 (3–11),95%CI(8.27–9.42)

33.5

US$ 25,627

€ 22,411.5

VAP

27(15–41),95%CI(26.77–34.39)

6.0 (3–11),95%CI(8.27–9.42)

21

US$ 16,065

€ 14,049

CLA-BSI

30(20–43),95%CI(23.13–38.59)

6.0 (3–11),95%CI(8.27–9.42)

24

US$ 18,360

€ 16,056

CA-UTI

29.00(14.5–43.5),95%CI(26.69–35.76)

6.0 (3–11),95%CI(8.27–9.42)

23

US$ 17,595

€ 15,387

Additional cost of therapy in observed period

   

US$ 1413,480 /1 year

€ 1236,378 /1 year

  1. Legend: real mean value cost of one patient-day was € 669 = US$ 765
  2. Abbreviations: CA-UTI catheter-associated urinary tract infection; CI confidence interval; CLA-BSI central line-associated bloodstream infection; DA-HAI device-associated health care-associated infections; IQR interquartile range; LOS length of stay; n number of patients with infections or number of days; VAP ventilator-associated pneumonia